Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

D-915

Supelco

Desalkylflurazepam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C15H10ClFN2O
Numero CAS:
2886-65-9
Peso molecolare:
288.70
Numero CE:
200-659-6
Numero MDL:
MFCD00083443
Codice UNSPSC:
41116107
NACRES:
NA.24
Prezzi e disponibilità al momento non sono disponibili Contatta l'Assistenza Tecnica.

Grado

certified reference material

Livello qualitativo

300

Stato

liquid

Caratteristiche

Snap-N-Spike®/Snap-N-Shoot®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

Concentrazione

1.0 mg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

clinical testing

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

Fc1ccccc1C2=NCC(=O)Nc3ccc(Cl)cc23

InChI

1S/C15H10ClFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)
UVCOILFBWYKHHB-UHFFFAOYSA-N

Descrizione generale

Desalkylflurazepam, also known as N-desalkyl-2-oxoquazepam, is a long-acting metabolite of the benzodiazepine drug flurazepam. Flurazepam is sold unde the trade names Dalmane and Dalmadorm for the treatment of mild to moderate insomnia. This Certified Spiking Solution® is suited for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis or urine drug testing.

Applicazioni


  • Pharmacokinetic profiling: Research on flurazepam metabolites, including Desalkylflurazepam, utilizes high-performance liquid chromatography for detailed pharmacokinetic studies in rats, providing essential data for understanding drug behavior and metabolism (Lau et al., 1987).

  • Neuroscience tool: Desalkylflurazepam is applied in neuroscience research to understand the dynamics of benzodiazepine binding on living cells, utilizing small ligands in fluorescence correlation spectroscopy, a method pivotal for real-time molecular interactions study (Hegener et al., 2002).

  • Drug testing applications: The compound is used in the development of analytical techniques like ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS/MS) for the detection of benzodiazepines in hair, useful in workplace drug testing and forensic science (Ramírez Fernández et al., 2015).

  • Toxicological analysis: Desalkylflurazepam serves as a reference standard in forensic toxicology to facilitate the rapid determination of benzodiazepines and their metabolites in biological samples, crucial for accurate and swift diagnostic purposes (Jeong et al., 2015).

  • Immunosorbent assay applications: This benzodiazepine metabolite is instrumental in examining cross-reactivity of psychoactive substances in enzyme-linked immunosorbent assay (ELISA) techniques, enhancing drug testing capabilities in clinical settings (Cieri et al., 2024).

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

D-924

Desalkylflurazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-003

Flurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-901

2-Hydroxyethylflurazepam solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-902

2-Hydroxyethylflurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-919

2-Hydroxyethylflurazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-923

2-Hydroxyethylflurazepam-d4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes,Central nervous system

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Elenchi normativi

Forniamo informazioni su eventuali restrizioni prevalentemente per i prodotti chimici. Per altre tipologie di prodotto siamo in grado di fornire soltanto informazioni limitate. Nessuna segnalazione significa che nessuno dei componenti è citato in un elenco. È dovere dell’utilizzatore assicurarsi che il prodotto venga impiegato in maniera sicura e a norme di legge.

EU REACH Annex XVII (Restriction List)

CAS No.

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

W Sieghart
Neuroscience letters, 38(1), 73-78 (1983-07-15)
The potency of several new benzodiazepines as inhibitors of [3H]flunitrazepam binding was investigated in membranes from rat cerebellum or hippocampus. It was found that quazepam and two of its metabolites have a higher affinity for benzodiazepine receptors in cerebellum than
N Zampaglione et al.
Drug metabolism and disposition: the biological fate of chemicals, 13(1), 25-29 (1985-01-01)
The absorption, metabolism, and excretion of quazepam, a new benzodiazepine hypnotic, was investigated in six normal male volunteers after oral administration of 25 mg 14C-quazepam in solution. Quazepam was well absorbed. Plasma radioactivity peaked (324.6 ng quazepam eq/ml) 1.75 hr
Kimiyasu Kato et al.
Therapeutic drug monitoring, 25(4), 473-477 (2003-07-29)
The effects of itraconazole, a potent inhibitor of cytochrome P450 (CYP) 3A4, on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug were studied. Ten healthy male volunteers received itraconazole 100
[Pharmacokinetics of the two major metabolites of ethyl loflazepate (CM6912) in dogs and humans. Simulation by a digital computer].
M Ito et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 106(8), 703-708 (1986-08-01)
H Morishita et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 86(1), 71-85 (1985-07-01)
Pharmacodynamic effects of ethyl 7-chloro-2,3-dihydro-5-(2-fluorophenyl)-2-oxo-1H-1,4- benzodiazepine-3-carboxylate (CM6912), a new benzodiazepine derivative, and its main metabolites (CM6913 = M1, CM7116 = M2) on the peripheral systems were investigated in several species of animals. In pentobarbital-anesthetized rabbits, CM6912 and M2 (1 or
Visualizza tutti i documenti correlati

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.